Laureate Pharma, Inc. has entered into a cGMP contract manufacturing agreement with Enobia Pharma, a biotechnology company developing an enzyme replacement therapy for the treatment of hypophosphatasia. Under the agreement, Laureate will produce Enobia’s fusion protein for treatment of hypophosphatasia, a rare, and potentially fatal metabolic bone disease characterized by skeletal hypomineralization. Terms of the agreement were not disclosed.

“We are delighted by the confidence Enobia has shown by continuing to utilize our specialized experience in the manufacture of fusion proteins,” said Robert J. Broeze, president and chief executive officer of Laureate. “We have a successful relationship with Enobia and will work with them closely to help them achieve their manufacturing objectives.”

“Our partnership with Laureate is an important component of our manufacturing strategy. We look forward to our partnership with Laureate and advancing our hypophosphatasia program into the clinic,” said Robert Heft, president and chief executive officer of Enobia.